Call for entries for the Dr John Hinds Scholarship

Monday, 02 March 2020

Call for entries for the Dr John Hinds Scholarship

Craigavon, N.I., 3 Mar 2020 – The College of Paramedics, in association with Galen the privately owned pharmaceutical sales and marketing company, is calling on all levels of pre-hospital responders on the island of Ireland, to take part in this exciting opportunity to win a place at the much coveted Anaesthesia Trauma and Critical Care (ATACC) course, widely accepted as the most advanced trauma course currently available across the globe.

This Scholarship is presented in memory of the late Dr John Hinds, who was held in high regard as an inspirational leader by paramedics and emergency medical technicians and indeed by anyone with an interest in pre-hospital care within Ireland. He selflessly gave a huge amount of his own time to educating and supporting paramedics and ambulance staff throughout the Island of Ireland; consequently, a scholarship for those colleagues is a fitting and practical way to preserve the memory of such a well-respected colleague and medical professional.

Entrants are required to write a case study, written to protect patient confidentiality, using original text, and with all appropriate references included. It must be countersigned by a paramedic colleague who is prepared to confirm that your submission is a genuine case study. Submissions should be 750–1,000 words, excluding references and appendices.

The recipient of the Scholarship will be funded to attend an ATACC course in the UK, in addition to associated travel costs.

Dr Dennise Broderick, Galen’s Managing Directory & President, stated “This award provides a unique opportunity for healthcare professionals to advance their expertise and gain access to a highly coveted training programme.

She added, “Dr Hinds was an incredibly inspirational individual who dedicated his life to helping others and Galen is therefore proud to support this annual scholarship programme in his honour.”

As a condition of the award, the recipient will be required to submit their case study for publication in Paramedic INSIGHT, along with a follow-up article that describes the experience attending the ATACC course.

Submissions must be made using the Dr John Hinds Scholarship Award Entry Form - link and submitted via email to awards@collegeofparamedics.co.uk. The College Honours and Awards Committee will then select the winning piece. 

Submissions should be sent to awards@collegeofparamedics.co.uk and must be received by 1200hrs on 6th April 2020.

The award will be presented to the recipient on 13th May 2020 at the College of Paramedics Awards ceremony at the Hilton Birmingham Metropole, Birmingham.

2019 recipient, David Murtagh, commented “I was honoured to be selected as the inaugural recipient of the Dr John Hinds Scholarship. The Anaesthesia Trauma & Critical Care (ATACC) course offered three days of immersive, high-fidelity simulations involving wrecked cars/trains/buildings, local trauma units and major trauma centres. These were interspersed with practical skills stations and up-to-date relevant lectures, all delivered by a large and expert international faculty.  The training I underwent highlighted the standard of trauma care we should be delivering, not just within a major trauma-centre setting, but also throughout our local emergency departments and in our communities.”

David is a Paramedic registered with the Pre-Hospital Emergency Care Council in the Republic of Ireland and has been working for the National Ambulance Service for three years. He is also an experienced mountain and cave rescue volunteer.

Notes to editors

About Galen

Established in 1968, Galen is a privately owned pharmaceutical sales and marketing company, headquartered in Craigavon (Northern Ireland), with products in therapy areas including gastroenterology, pain management and dermatology.

As a subsidiary of Galen Limited, Galen US also has a growing presence in select conditions such as those requiring topical anaesthesia. The company plans to continue expanding its portfolio with selected specialty products on an international basis. By combining innovation in product development with competitive pricing, Galen aims to work in partnership with healthcare professionals and patients to create real, long-term value. Visit: www.galen-pharma.com

About Almac Group

Galen is a member of the Almac Group. The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across, and beyond, the drug development lifecycle to the pharmaceutical and biotech sectors globally.

Almac’s innovative services range from R&D, biomarker discovery development and commercialisation, API manufacture, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture, product development and marketing.

The international company is a privately owned organisation that has grown organically over the past five decades and now employs over 5,600 highly skilled personnel across 18 facilities including Europe, the US and Asia.

For further information please visit www.almacgroup.com.

About The ATACC Group

The ATACC Group is a medical and specialist led organisation principally driven by people with a background in health care, UK emergency services and associated professional industries. They are trusted providers of education and training courses to a wide variety of healthcare professionals and emergency care providers. In addition to education and training provision they offer medical oversight and clinical governance services to UK emergency services and emergency response teams.

For further information please visit  https://www.ataccgroup.com/

References

  1. Galen. PKU Easy Microtabs datasheet.
  2. MacDonald A, Smith A, de Silva S, et al. The personal burden for caregivers of children with phenylketonuria: A cross-sectional study investigating time burden and costs in the UK. Molecular Genetics and Metabolism Reports 2016;9:1-5.
  3. NHS. Phenylketonuria. Available at: https://www.nhs.uk/conditions/phenylketonuria/.
  4. Ford S, O’Driscoll M, MacDonald A. Living with Phenylketonuria: Lessons from the PKU community. Molecular Genetics and Metabolism Reports 2018;17:57–63.
  5. Giovannini M et al. (2014) Randomized Controlled Trial of a Protein Substitute with Prolonged Release on the Protein Status of Children with Phenylketonuria, Journal of the American College of Nutrition, 33:2, 103-110, DOI:1080/07315724.2013.857281

MAT-POA-UK-000003